Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First European Cell Therapy Is Commercial Flop

Executive Summary

The first cell-based product to be approved in Europe, the TiGenix-developed and Sobi-marketed ChondroCelect, has met an ignominious end with the withdrawal of its marketing authorization. However, TiGenix has entered into an agreement with Takeda for ex-US rights to its next product candidate.

Advertisement

Related Content

Decade-Old Advanced Therapy Set For EU Approval
ReGenMed Group Wants Fixes To Ensure Proper Use Of Hospital Exemption In EU
TiGenix Raises $26m As Fistula Therapy Continues To Fizz
Cell Therapy Developers Debate Challenges As Big Pharma Drags Its Feet
First product through EU's advanced therapies regulation gets approval renewed
Sobi signs licencing deal for TiGenix's cell-based therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel